Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084.

Journal Article (Clinical Trial;Journal Article;Multicenter Study)

OBJECTIVE: The objective of the study was to determine whether protease inhibitors increase glucose intolerance and insulin resistance in pregnancy. STUDY DESIGN: In this multicenter, prospective, observational study, 149 human immunodeficiency virus-1-infected pregnant women had fasting insulin, glucose, and C-peptide measured followed by a 1 hour, 50 g glucose test. Glucose intolerance was defined as a 1 hour glucose greater than 130 mg/dL. Glucose intolerance, homeostasis model assessment of insulin resistance and pancreatic beta-cell function, and pregnancy outcomes were compared between those taking protease inhibitors and those not. RESULTS: Fifty-seven of 149 subjects (38%) had glucose intolerance. Body mass index, Hispanic ethnicity, and maternal age, but not protease inhibitors, were associated with glucose intolerance. There were no differences in insulin resistance, beta-cell function, or pregnancy outcome associated with protease inhibitor use. CONCLUSIONS: Protease inhibitors do not increase risk of glucose intolerance or insulin resistance among pregnant women.

Full Text

Duke Authors

Cited Authors

  • Hitti, J; Andersen, J; McComsey, G; Liu, T; Melvin, A; Smith, L; Stek, A; Aberg, J; Hull, A; Alston-Smith, B; Watts, DH; Livingston, E; AIDS Clinical Trials Group 5084 Study Team,

Published Date

  • April 2007

Published In

Volume / Issue

  • 196 / 4

Start / End Page

  • 331.e1 - 331.e7

PubMed ID

  • 17403409

Electronic International Standard Serial Number (EISSN)

  • 1097-6868

Digital Object Identifier (DOI)

  • 10.1016/j.ajog.2006.11.037


  • eng

Conference Location

  • United States